The Top 5 Biosimilar Articles for the Week of February 8

Here are the top 5 biosimilar articles for the week of February 8, 2021.

Hi, I’m Skylar Jeremias for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.

Here are the top 5 biosimilar articles for the week of February 8, 2021.

Number 5: An 80-week observational studysuggests a non-medical switch from infliximab to SB2 is “a feasible option” for patients with inflammatory bowel diseases.

Number 4: A patient in a hospital outpatient setting was 42% less likely to receive a filgrastim biosimilar than a patient in an office setting, but 73% more likely to receive an infliximab biosimilar, according to a large, cross-sectional study.

Number 3: Biosimilar competition took a big chunk of revenue from Roche's aging blockbusters in 2020, and the company is banking on its newer medicines to drive fresh revenue growth.

Number 2: Celltrion Healthcare has received Canadian authorization to market a subcutaneous formulation of the infliximab biosimilar Remsima (Remsima SC; CT-P13).

Number 1: During its 2020 earnings call, Amgen described how a double-edged biosimilars sword has worked for and against the company's profit margin.

To read all of these articles and more, visit centerforbiosimilars.com.